Eli Lilly and Company (NYSE:LLY) Shares Acquired by Sage Advisors LLC

Sage Advisors LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,677 shares of the company’s stock after purchasing an additional 25 shares during the period. Eli Lilly and Company accounts for 13.0% of Sage Advisors LLC’s investment portfolio, making the stock its 4th largest holding. Sage Advisors LLC’s holdings in Eli Lilly and Company were worth $16,547,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after acquiring an additional 1,620 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Eli Lilly and Company by 6.6% in the first quarter. Acadian Asset Management LLC now owns 36,897 shares of the company’s stock valued at $28,699,000 after buying an additional 2,289 shares in the last quarter. Edgestream Partners L.P. grew its holdings in Eli Lilly and Company by 13.8% during the first quarter. Edgestream Partners L.P. now owns 5,348 shares of the company’s stock worth $4,161,000 after acquiring an additional 649 shares during the period. Covestor Ltd raised its position in Eli Lilly and Company by 6.5% in the first quarter. Covestor Ltd now owns 296 shares of the company’s stock worth $230,000 after acquiring an additional 18 shares in the last quarter. Finally, Alley Investment Management Company LLC lifted its holdings in Eli Lilly and Company by 0.4% in the first quarter. Alley Investment Management Company LLC now owns 10,623 shares of the company’s stock valued at $8,264,000 after acquiring an additional 38 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 4.9 %

LLY opened at $746.20 on Friday. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock has a market capitalization of $708.38 billion, a PE ratio of 80.67, a P/E/G ratio of 2.82 and a beta of 0.43. The firm’s fifty day moving average price is $882.65 and its 200 day moving average price is $870.38.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 EPS. As a group, research analysts expect that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.70%. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Truist Financial boosted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Wolfe Research assumed coverage on shares of Eli Lilly and Company in a report on Friday. They set an “outperform” rating and a $1,000.00 target price for the company. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.